Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06395948 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating APG777 in Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis, sponsored by Apogee Therapeutics.

Active
Registry status
Phase 2
Development phase
470
Enrollment target
20
Study locations

NCT06395948 is a Phase 2 study of Atopic Dermatitis that is active but no longer recruiting, run by Apogee Therapeutics. The registered enrollment target is 470 participants, below the 606-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06395948, a Phase 2 study of Atopic Dermatitis, is active but no longer recruiting, sponsored by Apogee Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
470 participants
Enrollment target
20
Study locations

Study Summary

This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.

Conditions Studied

Atopic Dermatitis

Interventions

  • DRUG Placebo
  • DRUG APG777

Study Locations (20)

California

  • Investigational Site - Fountain Valley
  • Investigational Site - Los Angeles
  • Investigational Site - San Diego

Florida

  • Investigational Site - Coral Gables
  • Investigational Site - Jacksonville
  • Investigational Site - Margate

Illinois

  • Investigational Site - Chicago
  • Investigational Site - Skokie

Michigan

  • Investigational Site - Detroit
  • Investigational Site - Troy

Ohio

  • Investigational Site - Boardman
  • Investigational Site - Mason

Connecticut

  • Investigational Site - New Haven

Georgia

  • Investigational Site - Douglasville

Indiana

  • Investigational Site - West Lafayette

Trial Details

FieldValue
Enrollment Target 470 participants
Start Date 2024-04-29
Est. Completion 2028-06
Phase Phase 2

Sponsor

Apogee Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06395948

The ClinicalTrials.gov registry entry for NCT06395948 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 606-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (22% lower). The listed sponsor is Apogee Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06395948 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06395948 about?

NCT06395948 is a clinical study titled "A Study Evaluating APG777 in Atopic Dermatitis". This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777...

What is the current status of trial NCT06395948?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 470 participants. The study started on 2024-04-29. Estimated completion is 2028-06.

What conditions does trial NCT06395948 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT06395948?

The interventions under investigation include: Placebo (DRUG), APG777 (DRUG).

Who is sponsoring clinical trial NCT06395948?

This trial is sponsored by Apogee Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06395948 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.